- What else after the failure of the first line EFGR-TKI treatment2015 | Faculty of Medicine in Pilsen
- KRAS (G12S) mutation in a patient with NSCLC treated with erlotinib – a case report2013 | Faculty of Medicine in Pilsen
- Lung adenocarcinoma with two simultaneous driving mutations2013 | Faculty of Medicine in Pilsen
- Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC2013 | Faculty of Medicine in Pilsen
- Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation2015 | Faculty of Medicine in Pilsen, Faculty of Science
- The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC2014 | Faculty of Medicine in Pilsen
- Tolerancy of treatment with afatinib on our group of patients2014 | Faculty of Medicine in Pilsen
- Gene Mutations in Squamous Cell NSCLC: Insignificance of EGFR, KRAS and PIK3CA Mutations in Prediction of EGFR-TKI Treatment Efficacy2013 | Faculty of Medicine in Pilsen
- Osimertinib - a new oral third-generation EGFR TKI2017 | Publication without faculty affiliation
- Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report2015 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- Afatinib - drug profile2017 | Publication without faculty affiliation
- Erlotinib in the treatment of advanced squamous cell NSCLC2013 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy2013 | Faculty of Medicine in Pilsen
- High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib2015 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Science
- Case studies of patients treated with osimertinib2019 | Second Faculty of Medicine
- Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib2016 | Faculty of Medicine in Pilsen, Faculty of Science
- Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib2014 | Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Science
- Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study2018 | First Faculty of Medicine
- Antiangiogenic therapy of lung cancer2018 | Second Faculty of Medicine
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Lung adenocarcinoma with a rare EGFR mutation and infrequent resistance to treatment2022 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations2003 | First Faculty of Medicine
- Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations2003 | Faculty of Physical Education and Sport
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop2010 | First Faculty of Medicine
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
- Current position of afatinib in the therapy of non-small cell lung carcinoma2017 | Publication without faculty affiliation
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer2013 | Faculty of Medicine in Pilsen
